A detailed history of Royal Bank Of Canada transactions in Cor Medix Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 18,862 shares of CRMD stock, worth $229,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,862
Previous 13,889 35.81%
Holding current value
$229,550
Previous $60,000 153.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.64 - $8.23 $18,101 - $40,927
4,973 Added 35.81%
18,862 $152,000
Q2 2024

Aug 14, 2024

BUY
$4.08 - $6.39 $28,882 - $45,234
7,079 Added 103.95%
13,889 $60,000
Q1 2024

Nov 05, 2024

SELL
$2.94 - $4.24 $20,812 - $30,014
-7,079 Reduced 50.97%
6,810 $28,000
Q1 2024

May 15, 2024

SELL
$2.94 - $4.24 $39,304 - $56,684
-13,369 Reduced 66.25%
6,810 $28,000
Q4 2023

Feb 14, 2024

BUY
$3.0 - $4.01 $34,470 - $46,074
11,490 Added 132.24%
20,179 $75,000
Q3 2023

Nov 14, 2023

SELL
$3.6 - $4.46 $9,316 - $11,542
-2,588 Reduced 22.95%
8,689 $32,000
Q2 2023

Aug 14, 2023

BUY
$3.94 - $5.8 $44,431 - $65,406
11,277 New
11,277 $44,000
Q3 2022

Nov 14, 2022

BUY
$2.82 - $7.52 $45 - $120
16 New
16 $0
Q2 2022

Aug 15, 2022

SELL
$2.73 - $5.61 $6,355 - $13,060
-2,328 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.83 - $6.24 $21,704 - $35,362
-5,667 Reduced 70.88%
2,328 $13,000
Q4 2021

Feb 14, 2022

BUY
$4.47 - $5.56 $12,815 - $15,940
2,867 Added 55.91%
7,995 $36,000
Q3 2021

Nov 15, 2021

BUY
$4.46 - $7.11 $11,279 - $17,981
2,529 Added 97.31%
5,128 $24,000
Q2 2021

Aug 16, 2021

BUY
$6.05 - $10.09 $15,723 - $26,223
2,599 New
2,599 $18,000

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $502M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.